From Université Catholique de Louvain, Brussels, Belgium (S.L., J.-L.V., C.d.M., A.P.); Mayo Clinic College of Medicine, Rochester, MN (H.I.M., M.H., J.M., M.-A.C., M.E.-S.); University of Bologna, Italy (F.G., A.R.); Inserm, ERI-12, University Hospital, Amiens, France (C.T., D.R., C.S.); Aix-Marseille Université, Marseille, France (J.-F.A.); University of Modena, Italy (A.B.); and Cleveland Clinic, Department of Thoracic and Cardiac Surgery, OH (R.M.S.).
Circulation. 2017 Jan 31;135(5):410-422. doi: 10.1161/CIRCULATIONAHA.116.023340. Epub 2016 Nov 29.
Mitral valve (MV) repair is preferred over replacement in clinical guidelines and is an important determinant of the indication for surgery in degenerative mitral regurgitation. However, the level of evidence supporting current recommendations is low, and recent data cast doubts on its validity in the current era. Accordingly, the aim of the present study was to analyze very long-term outcome after MV repair and replacement for degenerative mitral regurgitation with a flail leaflet.
MIDA (Mitral Regurgitation International Database) is a multicenter registry enrolling patients with degenerative mitral regurgitation with a flail leaflet in 6 tertiary European and US centers. We analyzed the outcome after MV repair (n=1709) and replacement (n=213) overall, by propensity score matching, and by inverse probability-of-treatment weighting.
At baseline, patients undergoing MV repair were younger, had more comorbidities, and were more likely to present with a posterior leaflet prolapse than those undergoing MV replacement. After propensity score matching and inverse probability-of-treatment weighting, the 2 treatments groups were balanced, and absolute standardized differences were usually <10%, indicating adequate match. Operative mortality (defined as a death occurring within 30 days from surgery or during the same hospitalization) was lower after MV repair than after replacement in both the entire population (1.3% versus 4.7%; P<0.001) and the propensity-matched population (0.2% versus 4.4%; P<0.001). During a mean follow-up of 9.2 years, 552 deaths were observed, of which 207 were of cardiovascular origin. Twenty-year survival was better after MV repair than after MV replacement in both the entire population (46% versus 23%; P<0.001) and the matched population (41% versus 24%; P<0.001). Similar superiority of MV repair was obtained in patient subsets on the basis of age, sex, or any stratification criteria (all P<0.001). MV repair was also associated with reduced incidence of reoperations and valve-related complications.
Among patients with degenerative mitral regurgitation with a flail leaflet referred to mitral surgery, MV repair was associated with lower operative mortality, better long-term survival, and fewer valve-related complications compared with MV replacement.
临床指南中优先选择二尖瓣(MV)修复而非置换,这也是退行性二尖瓣反流手术适应证的重要决定因素。然而,支持当前建议的证据水平较低,并且最近的数据对其在当前时代的有效性提出了质疑。因此,本研究旨在分析退行性二尖瓣反流伴连枷瓣的 MV 修复和置换的非常长期结果。
MIDA(二尖瓣反流国际数据库)是一个多中心注册中心,在欧洲和美国的 6 个三级中心招募退行性二尖瓣反流伴连枷瓣的患者。我们总体上分析了 MV 修复(n=1709)和置换(n=213)的结果,通过倾向评分匹配和逆概率治疗加权进行分析。
在基线时,接受 MV 修复的患者比接受 MV 置换的患者年龄更小,合并症更多,且更可能出现后瓣叶脱垂。经过倾向评分匹配和逆概率治疗加权后,两组治疗患者得到平衡,且绝对标准化差异通常<10%,表明匹配充分。手术死亡率(定义为手术 30 天内或同一住院期间死亡)在整个人群中,MV 修复低于 MV 置换(1.3% vs. 4.7%;P<0.001)和倾向评分匹配人群(0.2% vs. 4.4%;P<0.001)。在平均 9.2 年的随访期间,观察到 552 例死亡,其中 207 例为心血管原因。在整个人群(46% vs. 23%;P<0.001)和匹配人群(41% vs. 24%;P<0.001)中,20 年生存率 MV 修复优于 MV 置换。根据年龄、性别或任何分层标准(均 P<0.001),MV 修复的优势在患者亚组中也得到了相似的体现。MV 修复还与减少再次手术和瓣膜相关并发症的发生率相关。
在退行性二尖瓣反流伴连枷瓣的患者中,与 MV 置换相比,MV 修复与手术死亡率降低、长期生存率提高和瓣膜相关并发症减少相关。